Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients.
cirrhosis
endotoxin
microbiome
rifaximin
Journal
Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404
Informations de publication
Date de publication:
29 Mar 2020
29 Mar 2020
Historique:
received:
07
03
2020
revised:
24
03
2020
accepted:
26
03
2020
entrez:
3
4
2020
pubmed:
3
4
2020
medline:
3
4
2020
Statut:
epublish
Résumé
Rifaximin is a poorly absorbable antibiotic against hepatic encephalopathy (HE). This observational study aimed to elucidate the effect of rifaximin on intestinal permeability and gut microbiota in patients with decompensated cirrhosis. Thirty patients with decompensated cirrhosis were assessed by ammonia level, neuropsychological testing, endotoxin activity (EA), and serum proinflammatory cytokines at baseline and after four weeks of rifaximin treatment (1200 mg/day). Intestinal permeability was indicated by serum soluble CD163 (sCD163), mannose receptor (sMR), and zonulin levels. To evaluate the gut microbiome, 16S ribosomal RNA gene sequencing was applied. Rifaximin ameliorated hyperammonemia and cognitive dysfunction, although it did not change the serum proinflammatory cytokine levels. It decreased EA levels as well as serum levels of sCD163 and sMR, but not zonulin, and both decreases in sCD163 and sMR showed positive correlations with EA decrease (ΔsCD163: Correlation coefficient (R) = 0.680,
Identifiants
pubmed: 32235367
pii: antibiotics9040145
doi: 10.3390/antibiotics9040145
pmc: PMC7235723
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
Funding: This research received no external funding
Références
PLoS One. 2013;8(4):e60042
pubmed: 23565181
Appl Environ Microbiol. 2009 Dec;75(23):7537-41
pubmed: 19801464
Mol Med Rep. 2015 Mar;11(3):1693-700
pubmed: 25421042
Appl Environ Microbiol. 2007 Aug;73(16):5261-7
pubmed: 17586664
Nat Rev Gastroenterol Hepatol. 2010 Sep;7(9):515-25
pubmed: 20703237
J Endocr Soc. 2019 Jun 26;3(9):1641-1651
pubmed: 31428718
Am J Gastroenterol. 2010 Feb;105(2):323-7
pubmed: 19844200
Gut Microbes. 2014 Jul 1;5(4):571-5
pubmed: 25244596
J Hepatol. 2014 Sep;61(3):642-59
pubmed: 25015420
Tissue Barriers. 2016 Oct 21;4(4):e1251384
pubmed: 28123927
Nature. 2001 Jan 11;409(6817):198-201
pubmed: 11196644
World J Hepatol. 2015 Mar 27;7(3):425-42
pubmed: 25848468
J Hepatol. 2005;42 Suppl(1):S45-53
pubmed: 15777572
Am J Physiol Gastrointest Liver Physiol. 2012 Sep 15;303(6):G675-85
pubmed: 22821944
Gastroenterology. 1978 Sep;75(3):462-9
pubmed: 680502
J Gastroenterol Hepatol. 2018 Feb;33(2):443-452
pubmed: 28573746
Brief Bioinform. 2012 Nov;13(6):656-68
pubmed: 22772836
Am J Gastroenterol. 1999 Jan;94(1):200-7
pubmed: 9934756
J Pharmacol Exp Ther. 2007 Jul;322(1):391-8
pubmed: 17442842
Gut. 2013 Aug;62(8):1231-2
pubmed: 23442440
Hepatogastroenterology. 2003 Sep-Oct;50(53):1482-6
pubmed: 14571769
Int J Clin Exp Med. 2015 Feb 15;8(2):2954-7
pubmed: 25932262
J Hepatol. 1995 Feb;22(2):165-72
pubmed: 7790704
Hepatol Res. 2017 Nov;47(12):1335-1339
pubmed: 28066966
Dig Liver Dis. 2012 Dec;44(12):1027-31
pubmed: 22883217
Clin Chem Lab Med. 2014 Mar;52(3):453-61
pubmed: 24114918
J Inflamm (Lond). 2013 Mar 06;10(1):8
pubmed: 23510603
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Liver Int. 2013 Nov;33(10):1457-69
pubmed: 23879434
Annu Rev Microbiol. 1985;39:175-93
pubmed: 3904599
Dig Liver Dis. 2010 Mar;42(3):200-4
pubmed: 19502117
Hepatology. 2017 Feb;65(2):571-581
pubmed: 27641757
World J Gastroenterol. 2017 Dec 21;23(47):8355-8366
pubmed: 29307995
J Gastroenterol Hepatol. 2018 Jan;33(1):307-314
pubmed: 28671712
Hepatobiliary Pancreat Dis Int. 2002 Nov;1(4):510-4
pubmed: 14607676
Gut. 2007 Jan;56(1):6-8
pubmed: 17172583
Nat Rev Immunol. 2009 Nov;9(11):799-809
pubmed: 19855405
Nat Clin Pract Gastroenterol Hepatol. 2007 Dec;4(12):677-85
pubmed: 18043677
Am J Pathol. 2013 Feb;182(2):375-87
pubmed: 23201091
PLoS One. 2018 Sep 5;13(9):e0203200
pubmed: 30183743
J Hepatol. 2000 May;32(5):742-7
pubmed: 10845660
Front Pharmacol. 2016 May 09;7:120
pubmed: 27242527
PLoS One. 2012;7(5):e37160
pubmed: 22629362
Eur J Clin Invest. 2012 Apr;42(4):439-46
pubmed: 22023490
Eur J Clin Microbiol Infect Dis. 2014 Jan;33(1):117-22
pubmed: 24424890
Am J Gastroenterol. 2014 Nov;109(11):1749-56
pubmed: 25155228
Aliment Pharmacol Ther. 2018 Mar;47(5):657-664
pubmed: 29266346